Updates on human papillomavirus and genital warts and counseling messages from the 2010 sexually transmitted diseases treatment guidelines

Clinical Infectious Diseases

Volumn 53, Issue SUPPL. 3, 2011, Pages

  Dunne, Eileen F ^a   Friedman, Allison ^a   Datta, S Deblina ^a   Markowitz, Lauri E ^a   Workowski, Kimberly A ^a,b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN TEA EXTRACT; IMIQUIMOD; WART VIRUS VACCINE;

CANCER SCREENING; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; OINTMENT; PATIENT COUNSELING; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SEXUALLY TRANSMITTED DISEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VACCINATION; VIRUS DETECTION; VITILIGO; WART VIRUS;

ANTI-INFECTIVE AGENTS, LOCAL; ANTIVIRAL AGENTS; CATECHIN; CONDYLOMATA ACUMINATA; COUNSELING; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 81055144386     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir703     Document Type: Review

References (73)

1. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003; 88:63-73.
2. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24(Suppl 3):S3/11-25.
3. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467-75. (Pubitemid 40270113)
4. Garland SM, Steban M, SingsHL, JamesM, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase II trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199:805-14.
5. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132:277-84. (Pubitemid 28125180)
6. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87:1365-71.
7. Winer RL, Lee SK, Hughes JP, AdamDE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218-26. (Pubitemid 36152435)
8. Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007; 196:1128-36. (Pubitemid 47580267)
9. Hernandez BY, Wilkens LR, Zhu X, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 2008; 14:888-94. (Pubitemid 351838596)
10. Burchell AN, Tellier PP, Hanley J, Coutlée F, Franco EL. Human papillomavirus infections among couples in new sexual relationships. Epidemiology 2010; 21:31-7.
11. D'Souza G, Fakhry C, Sugar EA, et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 2007; 121:143-50. (Pubitemid 46753862)
12. Oriel JD. Natural history of genital warts. Br J Vener Dis 1971; 47:1-13.
13. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine, recommendations of the Advisory Committee for Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1-24.
14. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:626-9.
15. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43. (Pubitemid 46740303)
16. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
17. Food and Drug Administration. Product approval information-licensing action, package insert: Gardasil (quadrivalent human papillomavirus types 6, 11, 16 and 18 HPV), Merck & Co. Whitehouse Station, NJ: Food and Drug Administration, 2009. Available at: http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf. Accessed 23 March 2010.
18. Food and Drug Administration. Product approval information-licensing action, package insert: Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant ), GlaxoSmithKline biologicals.Whitehouse Station, NJ: Food and Drug Administration, 2009. Available at: http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/Approved Products/UCM186981.pdf. Accessed 23 April 2010.
19. Giuliano A, Palefsky J. on behalf of the male quadrivalent HPV vaccine efficacy trial study group. The efficacy of the quadrivalent HPV vaccine (types 6, 11, 16 and 18) in reducing the incidence of infection and HPVrelated disease in young men. Nice, France: Eurogen, 2008. Abstract.
20. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:630-2.
21. Palefsky J. for the Male Quadrivalent HPV Vaccine Efficacy Trial. Quadrivalent HPV vaccine efficacy against anal intraepithelial neoplasia in men having sex with men. Monte Carlo, France: Eurogin, 2010; SS 19-2.
22. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. New Engl J Med 2011; 364:401-12.
23. FDA News release. http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm237941.htm. Accessed January 2011.
24. Food andDrug Administration. Product approval information-licensing action, package insert. hc2 High-Risk HPV DNA Test. Available at: http://www.accessdata.fda.gov/cdrh-docs/pdf/P890064S009c.pdf. Accessed 23 April 2010.
25. Food andDrug Administration. Product approval information-licensing action, package insert. Cervista HPV HR test. Available at: http://www. accessdata.fda.gov/cdrh-docs/pdf8/P080014c.pdf. Accessed 23 April 2010.
26. Food andDrug Administration. Product approval information-licensing action, package insert. Cervista 16/18 test. Available at: http://www. accessdata.fda.gov/cdrh-docs/pdf8/P080015c.pdf. Accessed 23 April 2010.
27. Centers for Disease Control and Prevention. Cervical cancer screening recommendations. Available at: http://www.cdc.gov/cancer/cervical/pdf/ guidelines.pdf. Accessed January 2011.
28. ASSCP guidelines on use of Cervista-HPV 16/18 test. Available at: http://www.asccp.org/pdfs/consensus/hpv-genotyping-20090320.pdf. Accessed 23 April 2010.
29. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97:1072-9. (Pubitemid 41417924)
30. Jain N, Irwin K, Carlin L, Freeman C, Montano D, Kasprzyk D. Use of DNA tests for human papillomavirus infection by US clinicians, 2004. J Infect Dis 2007; 196:76-81. (Pubitemid 46982740)
31. Moriarty AT, Schwartz MR, Eversole G, et al. Human papillomavirus testing and reporting rates: practices of participants in the College of American Pathologists interlaboratory comparison program in gynecologic cytology in 2006. Arch Pathol Lab Med 2008; 132: 1290-4.
32. Solomon D, Schiffman M, Tarone R. ALTS study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93:293-9. (Pubitemid 32219816)
33. Widdice LE, Moscicki AB. Updated guidelines for papanicolaou tests, colposcopy, and human papillomavirus testing in adolescents. J Adolesc Health 2008; 43(Suppl 4):S41-51.
34. Food and Drug Administration. Product approval information-licensing action, package insert. VEREGENTM (Kunecatechins) ointment, 15%. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021902lbl.pdf. Accessed 23 April 2010.
35. Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts. Obstet Gynceol 2008; 111:1371-9.
36. Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 2008; 158:1329-38. (Pubitemid 351692865)
37. Gross G, Meyer KG, Pres H, Thieler C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Europ Acad Dermatol Venereol 2007; 21:1404-12. (Pubitemid 350020150)
38. Mashiah J, Brenner S. Possible mechanisms in the induction of vitiligolike hypopigmentation by topical imiquimod. Clinic Exp Dermatol 2007; 33:74-6. (Pubitemid 350308512)
39. Gotovtsheva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal frequency of imiquimod (Aldara) 5% creamfor the treatment of external genital warts in immunocompetent adults: a meta-analysis. Sex Transm Dis 2008; 35:346-51. (Pubitemid 351440773)
40. Garland SM, Waddell R, Mindel A, Denham IM, McCloskey JC. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int J STD AIDS 2006; 17:448-52. (Pubitemid 44049670)
41. Dolev JC, Maurer T, Springer G, et al. Incidence and risk factors for verrucae in women. AIDS 2008; 19:1213-9.
42. De Panfilis G, Melzani G, Mori G, Ghidini A, Graifenberghi S. Relapses after treatment of external genital warts aremore frequent inHIV-positive patients than in HIV-negative controls. Sex Transm Dis 2002; 29:121-5. (Pubitemid 34219624)
43. Silverberg MJ, Ahdieh L, Munoz A, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002; 29:427-35. (Pubitemid 34851777)
44. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006; 43:223-33.
45. Centers for Disease Control and Prevention , Kaplan JE, Benson C, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
46. Graziottin A, Serafini A. HPV infection in women: psychosexual impact of genital warts and intraepithelial lesions. J Sex Med 2009; 6:633-45.
47. McCaffery K, Waller J, Nazroo J, Wardle J. Social and psychological impact of HPV testing in cervical screening: a qualitative study. Sex Transm Infect 2006; 82:169-74.
48. Perrin KK, Daley EM, Naoom SF, et al. Women's reactions to HPV diagnosis: insights from in-depth interviews. Women Health 2006; 43:93-110. (Pubitemid 44523776)
49. Friedman A, Shepeard H. Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from CDC focus group research and implications for practice. Health Educ Behav 2007; 34:471-85.
50. McCree DH, Sharpe PA, Brandt HM, Robertson R. Preferences for sources of information about abnormal Pap tests and HPV in women tested for HPV. Prev Med 2006; 43:165-70. (Pubitemid 44354829)
51. Bertram CC, Magnussen L. Informational needs and the experiences of women with abnormal Papanicolaou smears. J Am Acad Nurse Pract 2008; 20:455-62.
52. Waller J, McCaffery K, Nazroo J, Wardle J. Making sense of the information about HPV in cervical screening: a qualitative study. Br J Cancer 2005; 92:265-70. (Pubitemid 40343139)
53. Clarke P, Ebel C, Catotti DN, Stewart S. The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 1996; 7:197-200. (Pubitemid 26191688)
54. Newton DC, McCabe M. Effects of sexually transmitted infection status, relationship status, and disclosure status on sexual self-concept. J Sex Res 2008; 45:187-92.
55. Reitano M. Counseling patients with genital warts: perspectives on human papillomavirus infection. Am J Med 1997; 102(5A Suppl): 38-43.
56. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. Br Med J 2004; 328:1293-9.
57. McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. Br J Obstet Gynecol 2004; 111:1437-43. (Pubitemid 39665037)
58. Linnehan MJ, Groce NE. Counseling and educational interventions for women with genital human papillomavirus infection. AIDS Patient Care STDS 2000; 14:439-45.
59. Anhang R, Wright TC Jr., Smock L, Goldie SJ. Women's desired information about human papillomavirus. Cancer 2004; 100:315-20. (Pubitemid 38063640)
60. Marlow LA, Waller J, Wardle J. The impact of human papillomavirus information on perceived risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 2009; 18:373-6.
61. Abercrombie PD. Improving adherence to abnormal Pap smear followup. J Obstet Gynecol Neonatal Nurs 2001; 30:80-8.
62. Khanna N, Phillips MD. Adherence to care plan in women with abnormal Papanicolaou smears: a review of barriers and interventions. J Am Board Fam Med 2001; 14:123-30. (Pubitemid 33705687)
63. McKee MD, Lurio J, Marantz P, Burton W, Mulvihill M. Barriers to follow-up of abnormal Papanicolaou smears in an urban community health center. Arch Fam Med 1999; 8:129-34.
64. McCaffery K, Forrest S, Waller J, Desai M, Szarewski A, Wardle J. Attitudes towards HPV testing: a qualitative study of beliefs among Indian, Pakistani, African-Caribbean and white British women in the UK. Br J Cancer 2003; 88:42-6. (Pubitemid 36241216)
65. Waller J, McCaffery K, Kitchener H, Nazroo J, Wardle J. Women's experiences of repeated HPV testing in the context of cervical cancer screening: a qualitative study. Psychooncology 2007; 16:196-204. (Pubitemid 46380543)
66. Papa D, Moore Simas TA, Reynolds M, Melnitsky H. Assessing the role of education in women's knowledge and acceptance of adjunct highrisk human papillomavirus testing for cervical cancer screening. J Low Genit Tract Dis 2009; 13:66-71.
67. Sharpe PA, Brandt HM, McCree DH. Knowledge and beliefs about abnormal pap test results and HPV among women with high-risk HPV: results from in-depth interviews. Women Health 2005; 42:107-33.
68. McCaffery K, Irwig L. Australian women's needs and preferences for information about human papillomavirus in cervical screening. J Med Screen 2005; 12:134-41. (Pubitemid 41337146)
69. Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol 2007; 110:87-95. (Pubitemid 47015705)
70. Erratum in: Obstet Gynecol. 2007;110(3):713.
71. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354:2645-5.
72. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003; 107:811-6. (Pubitemid 37339736)
73. Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003; 107:804-10. (Pubitemid 37339735)